Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas

This study has been completed.
Sponsor:
Information provided by:
XOMA (US) LLC
ClinicalTrials.gov Identifier:
NCT00051675
First received: January 14, 2003
Last updated: June 23, 2005
Last verified: September 2004
  Purpose

The purpose of this study is to evaluate the safety, immunogenicity, and tolerability of a monoclonal antibody administered subcutaneously in the treatment of advanced cancers of the ovary, breast, lung, prostate, colon or rectum that are either refractory to standard therapies or for which therapies that may potentially be of major benefit do not exist.


Condition Intervention Phase
Adenocarcinoma
Drug: ING-1(heMAb)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Multi-Dose, Phase I, Dose-Escalating Study of a Subcutaneously Administered Human-Engineered Monoclonal Antibody, ING-1(heMAb), in Subjects With Advanced Adenocarcinomas

Further study details as provided by XOMA (US) LLC:

Estimated Enrollment: 30
Study Start Date: July 2002
Estimated Study Completion Date: September 2003
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Subject has adenocarcinomas of the ovary, breast, lung, prostate, colon or rectum.
  2. Subject has an advanced metastatic adenocarcinoma that is either refractory to standard therapies or for which therapies that may potentially be of major benefit do not exist.
  3. Subject has measurable lesions. Subjects with prostate cancer can have non-measurable lesions.
  4. Subject may have prior radiation therapy if completed at least four weeks prior to study entry, the subject has recovered from the acute toxicities of that therapy, and measurable lesions are in a non-irradiated area.
  5. Subject may have prior chemotherapy, cytokine therapy or immunotherapy if completed at least four weeks prior to study entry and the subject has recovered from the acute toxicities of that therapy.
  6. Subjects with tumors responsive to hormone therapy may have prior hormonal therapy if completed at least four weeks prior to study entry. Hormonal therapy for prostate cancer may be continued but must not have been changed less than four weeks prior to study entry.
  7. Subject has a performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) scale.
  8. Subject has an estimated life expectancy of at least 12 weeks.
  9. Subject is at least 18 years of age.
  10. Subject has adequate organ function defined as follows:

    • Hematologic:

      • Platelets 100 × 109/L
      • Hemoglobin 9.0 g/dL
      • Total WBC count 3.5 × 109/L
      • PT/INR and PTT are within institutional limits in subjects who are not receiving therapeutic anticoagulation or low dose anticoagulants to maintain venous catheter patency (subjects on anti-coagulant therapy are allowed).
    • Hepatic:

      • Bilirubin 2.0 mg/dL
      • Aspartate transaminase (AST) and alanine transaminase (ALT) 3 times the upper limit of normal (AST and ALT 5 times the upper limit of normal is acceptable if liver has tumor involvement and the elevation is due to tumor involvement)
    • Renal: Serum creatinine 1.5 mg/dL
    • Pancreatic: Amylase and lipase upper limit of the normal (ULN)
  11. Signed informed consent form.
  12. Male and female subjects with reproductive potential must use an approved contraceptive method.
  13. Female subjects with reproductive potential must have a negative serum pregnancy test within seven days of study enrollment.

Exclusion Criteria

  1. Subject has serious concomitant systemic disorders incompatible with the study.
  2. Subject has used any other investigational agent within 30 days of study entry.
  3. Subject is pregnant or lactating.
  4. Subject has undergone a bone marrow transplant.
  5. Subject is known to be HIV+ or to have any other recognized immunodeficiency disease. (Note: As the mechanism of action of ING-1(heMAb) is ADCC, subjects need to be immunocompetent).
  6. Subject has a history of severe allergic or anaphylactic reactions to monoclonal antibodies or antibody fragments. (Note: For subjects who have received prior ING-1(heMAb), the HAHA titer should be negative.)
  7. Subject has concurrent or prior malignancy, except for adequately-treated basal cell or squamous cell skin cancer, adequately-treated non-invasive carcinomas or other cancer from which the subject has been disease-free for at least two years.
  8. Subject has an active auto-immune disease requiring chronic treatment.
  9. Subject is using or has used immunosuppressive drugs such as cyclosporine, ACTH or corticosteroids within four weeks prior to enrollment.
  10. Subject has brain metastases or a known history of brain metastases.
  11. Subject has a history of alcoholism or chronic pancreatitis or a family history of acute or chronic pancreatitis.
  12. Subject has hypertriglyceridemia ( Serum triglycerides 500 mg/dL).
  13. Subject has a history of gall bladder disease or gallstones (post-cholecystectomy subjects are allowed).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00051675

Locations
United States, New York
Jack D. Weiler Hospital of the Albert Einstein College of Medicine
Bronx, New York, United States, 10461
Sponsors and Collaborators
XOMA (US) LLC
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00051675     History of Changes
Other Study ID Numbers: INCA104
Study First Received: January 14, 2003
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by XOMA (US) LLC:
adenocarcinoma
monoclonal antibody

Additional relevant MeSH terms:
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Antibodies
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 23, 2014